What is the recommended treatment approach for antisynthetase syndrome, including initial high‑dose prednisone dosing, steroid‑sparing immunosuppressants, and options for refractory disease?

Treatment of Antisynthetase Syndrome

Initiate treatment with high-dose prednisone (0.5-1 mg/kg/day, typically 40-60 mg/day) combined with early steroid-sparing immunosuppression, using rituximab as first-line for severe interstitial lung disease (ILD) or refractory arthritis, and methotrexate or mycophenolate mofetil for less severe manifestations.

Initial Treatment Approach

High-Dose Glucocorticoids

Start with prednisone 0.5-1 mg/kg/day (maximum 60-80 mg/day) administered as a single morning dose before 9 am 1. For severe, life-threatening manifestations (particularly rapidly progressive ILD), consider IV methylprednisolone pulse therapy 500-1000 mg/day for 3-5 days before transitioning to oral therapy 2, 3.

The morning dosing is critical because exogenous corticosteroids suppress adrenocortical activity least when given at the time of maximal adrenal activity (2-8 am), minimizing HPA axis suppression 1.

Concurrent Immunosuppression Strategy

Do not use glucocorticoids as monotherapy. Early co-administration of immunosuppressants is essential for disease control and steroid-sparing 4.

For Severe or Rapidly Progressive ILD:

• First-line: Rituximab (standard dosing: 1000 mg IV on days 1 and 15, then every 6 months)
• Rituximab demonstrates superior 2-year progression-free survival compared to cyclophosphamide (HR 0.263,95% CI 0.094-0.732, P = 0.011) 5
• Particularly effective when baseline DLCO is reduced, which independently predicts poor outcomes 5
• Combined early treatment with corticosteroids, mycophenolate mofetil, and rituximab shows favorable outcomes in severe ILD with organizing pneumonia 6

For Moderate ILD or Initial Therapy:

• Mycophenolate mofetil 1000-2000 mg/day in divided doses
• Switch to rituximab if inadequate response within 3-6 months 4

For Predominant Myositis:

• First-line: Methotrexate 15-25 mg/week (oral or parenteral)
• If refractory, escalate to mycophenolate mofetil or rituximab 4

For Refractory Arthritis:

• Rituximab is the most effective option after methotrexate failure 4
• Methotrexate and other synthetic immunosuppressants show limited efficacy for antisynthetase-related arthritis 4

Alternative for Refractory Disease:

• Tocilizumab (IL-6 inhibitor) demonstrates long-lasting improvement across multiple manifestations (joint, muscle, lung) in patients refractory to rituximab, with sustained remission >10 years 7

Glucocorticoid Tapering Protocol

Rapid tapering is feasible and recommended when combined with early immunosuppression 4:

1. Weeks 1-4: Maintain initial high dose (0.5-1 mg/kg/day)
2. Months 2-3: Taper by 5-10 mg every 2 weeks to reach 20-30 mg/day
3. Months 4-6: Taper by 2.5-5 mg monthly to reach 10 mg/day
4. Months 6-12: Taper by 1-2.5 mg monthly, aiming for discontinuation by 6-12 months 4

Critical caveat: Taper more slowly if disease activity persists. Monitor closely for flares during the taper, particularly when reducing below 10 mg/day 1.

Supportive Measures

Mandatory Prophylaxis:

• Pneumocystis jiroveci prophylaxis: Trimethoprim-sulfamethoxazole 800/160 mg three times weekly or 400/80 mg daily when using cyclophosphamide or high-dose steroids (>20 mg prednisone equivalent for >3 weeks) 8
• Bone protection: Calcium and vitamin D supplementation; DEXA scan at baseline and every 1-2 years while on steroids 9
• GI prophylaxis: Proton pump inhibitor when using moderate-to-high dose steroids 10

Avoid Abrupt Withdrawal:

Never stop corticosteroids abruptly after long-term use. Gradual withdrawal over 4-6 weeks minimum is essential to prevent adrenal crisis 1.

Monitoring Strategy

• Clinical assessment: Monthly during induction, then every 3 months
• Pulmonary function tests (PFTs): Every 3-6 months for ILD patients
• Muscle enzymes (CK, aldolase): Monthly initially, then every 3 months
• Inflammatory markers (ESR, CRP): Every 1-3 months
• Imaging: Chest CT at 6-12 months for ILD patients 2, 3

Treatment Algorithm Summary

1. Severe/life-threatening disease (rapidly progressive ILD, severe myositis):

   • IV methylprednisolone 500-1000 mg/day × 3-5 days → oral prednisone 1 mg/kg/day
   • Plus rituximab (immediate initiation)

2. Moderate-severe disease:

   • Oral prednisone 0.5-1 mg/kg/day
   • Plus mycophenolate mofetil OR rituximab (based on ILD severity)

3. Predominant myositis without severe ILD:

   • Oral prednisone 0.5-1 mg/kg/day
   • Plus methotrexate 15-25 mg/week

4. Refractory to initial therapy:

   • Switch to rituximab (if not already used)
   • Consider tocilizumab for multi-refractory disease 7

Key principle: Early aggressive immunosuppression allows for rapid steroid tapering, minimizing glucocorticoid toxicity while maintaining disease control 4.